文献速递临床试验与 GCP

立体定向放疗治疗湿性年龄相关性黄斑变性(STAR):随机对照临床试验研究方案

StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
PubMed 文献 · Trials · 2016-11-24

STAR试验为多中心、双盲、随机、假照射对照临床研究,评估立体定向放疗(SRT)能否减少慢性活动性新生血管性年龄相关性黄斑变性(nAMD)患者所需的抗VEGF注射次数。受试者接受单次SRT(16 Gy或假照射)并同时基线玻璃体内注射0.5 mg雷珠单抗,此后每月随访24个月,按需给药。主要结局为前24个月按需雷珠单抗注射次数,目标样本量411例(2:1随机分配至放疗组)。

要点

  • STAR试验评估单次立体定向放疗(16 Gy)能否减少nAMD患者按需雷珠单抗注射次数。
  • 多中心、双盲、随机、假照射对照设计,目标样本量411例,放疗组与对照组按2:1随机分配。
  • 主要结局为前24个月按需雷珠单抗注射次数,随访至48个月以检查放射性视网膜病变。

核心结论

  • STAR试验的安全性及有效性结果将有助于确定立体定向放疗在慢性活动性nAMD管理中的作用。

研究设计与样本

  • STAR为多中心、双盲、随机、假照射对照临床试验,评估一种由Oraya(美国加州纽瓦克)制造、用于向nAMD病灶递送立体定向放疗的新设备。
  • 纳入慢性活动性nAMD受试者,接受单次SRT(16 Gy或假照射)并同时基线玻璃体内注射0.5 mg雷珠单抗。
  • 此后每月随访24个月,符合再治疗标准时给予雷珠单抗;另在36和48个月随访检查放射性视网膜病变。
  • 目标样本量411例,按2:1随机分配至放疗组,主要分析采用意向性治疗原则。

主要发现

  • 样本量411例(2:1随机分配至放疗组)设计用于以90%把握度、显著性水平(alpha)0.025(单侧两样本t检验)检测相对雷珠单抗单药治疗减少2.5次注射。
  • 该设计对视力在5个字母边际上的非劣效性检测把握度为97%。

关键数值与推荐

  • 主要结局为前24个月按需雷珠单抗注射次数。
  • 次要结局包括视力、病灶形态、生活质量及安全性。
  • 再治疗标准满足时在每月访视时给予雷珠单抗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard of care for neovascular age-related macular degeneration (nAMD) involves ongoing intravitreal injections of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF). The most commonly used anti-VEGF drugs are ranibizumab, bevacizumab and aflibercept. The main objective of the STAR trial is to determine if stereotactic radiotherapy can reduce the number of anti-VEGF injections that patients with nAMD require. METHODS/DESIGN: STAR is a multicentre, double-masked, randomised, sham-controlled clinical trial. It evaluates a new device (manufactured by Oraya, Newark, CA, USA) designed to deliver stereotactic radiotherapy (SRT) to nAMD lesions. The trial enrols participants with chronic, active nAMD. Participants receive a single SRT treatment (16 Gy or sham) with a concomitant baseline intravitreal injection of 0.5 mg ranibizumab. Thereafter, they attend every month for 24 months, and ranibizumab is administered at the visit if retreatment criteria are met. The primary outcome is the number of pro re nata ranibizumab injections during the first 24 months. Secondary outcomes include visual acuity, lesion morphology, quality of life and safety. Additional visits occur at 36 and 48 months to inspect for radiation retinopathy. The target sample size of 411 participants (randomised 2:1 in favour of radiation) is designed to detect a reduction of 2.5 injections against ranibizumab monotherapy, at 90% power, and a significance level (alpha) of 0.025 (one-sided two-sample t test). This gives 97% power to detect non-inferiority of visual acuity at a five-letter margin. The primary analyses will be by intention to treat. DISCUSSION: The safety and efficacy outcomes will help determine the role of SRT in the management of chronic, active nAMD. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number: ISRCTN12884465. Registered on 28 November 2014. ClinicalTrials.gov: NCT02243878 . Registered on 17 September 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Neffendorf JE, Desai R, Wang Y, et al. StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial. Trials. 2016. PMID: 27881184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。